A Phase 3 clinical trial (NCT06041217) investigating semaglutide for individuals with overweight or obesity reached its primary completion on 2025-04-02. The study, titled "A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range," evaluated an investigational dose of semaglutide against a placebo.
Background
Semaglutide is a medication currently used for various indications, including type 2 diabetes and chronic weight management. This particular study focused on its potential role in helping people with excess body weight, specifically those categorized as overweight or having obesity, achieve weight loss.
Trial design
The study, identified as NCT06041217, was a Phase 3 trial. It was designed to compare the weight loss achieved by participants taking semaglutide against those receiving a placebo. The trial enrolled 242 participants diagnosed with either overweight or obesity. The study duration was approximately 1 year, involving 12 clinic visits and 3 remote phone visits with study staff.
What this means
The primary completion of this Phase 3 trial signifies a significant milestone in the development pathway for semaglutide in the context of weight management. While specific outcome data is not yet available, the completion of this phase indicates that the study has gathered the necessary data to evaluate the efficacy and safety profile of semaglutide for this population. Future data releases will provide insights into the trial's findings regarding weight loss in individuals with overweight or obesity.
Source
Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06041217, titled "A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range," was posted on 2025-04-02 on clinicaltrials.gov.